About Portfolio  
blank
 

Gynion is a Women’s Health startup with a mission to offer millions of women worldwide safe, effective, and affordable in-office therapies helping to avoid unnecessary hysterectomies and improve and save lives.
Gynion is developing a therapeutic platform for multiple indications in gynecology and dermatology.
 

Menorrx is a therapy for Heavy Menstrual Bleeding (HMB). In the pre-clinical trial, Menorrx shows promise to be a safe and effective non-invasive in-office treatment. It is simpler, easier to use, and will cost significantly less than the alternatives. Because of the high cost and clinical limitations of the available options, millions of women receive no treatment or are compelled to undergo a hysterectomy. Menorrx presents a substantial opportunity to change that both in developed markets and low-resource countries.

 
Clarablex is a topical gel for deep tissue ablation. It is a treatment for multiple indications in gynecology and dermatology, including cervical intraepithelial neoplasia (CIN) caused by human papillomavirus (HPV) to prevent cervical cancer. In the pre-clinical trial, Clarablex demonstrates results that are expected to be sufficient to treat CIN2+.
 

 
Oleg Shikhman, MBA, MS Victoria Shikhman, ND Steven Goldstein, MD
Founder and CEO Founder and Founder and CMO
interim VP, Clinical Research
 

Nicole Shugrue Julie Gionfriddo Dana Dunn
Market Advisor Business Development Advisor Regulatory Advisor
Fiondella, Milone & LaSaracina Dunn Regulatory Associates
 

Malcolm Munro, MD

Amy Garcia, MD

Paul Blumenthal, MD

     
 

Tulay Okman Kiliç , MD

Juan Canela Oleaga, MD

 
 
medical device Bridge Innovations LinkedIn   medical device Bridge Innovations ecosystem phone  

Gynion, Clarablex and Menorrx are trademarks of Gynion, LLC

medical device Bridge Innovations incubator